Solutions
Advisory Services
Clinical Development
- Generics Development
- Clinical Operations
- Clinical Data Sciences
- Medical and Safety Services
- RWD & RWE Services
Post Marketing
- Safety Services
- Post marketing Studies
- Regulatory Affairs
How Navitas Life Sciences Increases Infectious Diseases and Vaccine Clinical Trials Success Rate
Close to World AIDS Day, our latest blog focuses on our expertise in conducting infectious disease clinical trials. We support multiple small to large pharma and life science companies to bring life-saving medicines to the market through well-managed clinical trials.
Navitas Life Sciences has over 30 years of experience conducting clinical trials, providing us with the unique capability to understand your key challenges and constitute established systems to run a successful trial. From phase I to phase IV, we support your organization from startup to closure and beyond with our regulatory insights and quality approach. Our services are backed by technology & analytics explicitly developed to meet daily challenges, giving you a competitive edge and enhanced success rate.
How we Support Infectious Disease/Immunology/Vaccine Clinical Trials and Increase Success Rate
Navitas Life Sciences has a highly-experienced team of specialists in Infectious Diseases/Immunology and Vaccine studies, with vast experience in designing, conducting and managing infectious disease clinical trials.
Global coverage with local knowledge
Strong local presence and partnerships in all areas of the globe to deliver according to regional requirements
Proven track record of exceptional delivery Across 20+ Therapy Areas related Indications
30+ years experience supporting the federal government, private sector and nonprofit organizations, with significant client satisfaction
Fully audited with no critical findings
40+ GCP and non-GCP audits and inspections
Significant efficiencies sought for every study
Streamlined start-up and lessons learned from previous studies
Senior management oversight of operational delivery
Strong core team with regular senior management review meetings and full executive support for project teams on a regular basis
Strong Relationship with Multiple Vaccines/ID-experienced Site Networks in US, EU and APAC Regions
VaxCorp, HyperCore, Platinum Research Network, Clin Edge, Investigator database of experienced Sites in APAC, Site Networks, and India COVID-19 Hotspots
Leverage Hard Earned Lessons Gained from Managing Efficient Infectious Disease Trials
Navitas Life Sciences has conducted over 550 clinical trials across 20+ therapeutic areas.
COVID-19 has entered the endemic stage in certain parts of the world, but it is important to take back the important lessons learnt. Navitas Life Sciences has conducted multiple infectious diseases clinical trials, including COVID-19, from phases I to IV.
Resilience in Managing Clinical Trials for Greater efficiency and Success
Navitas Life Sciences leverages its vast infectious disease clinical trial experience to build the necessary capabilities and deploy the right measures to enhance clinical trial efficiency.
Learn about Navitas Life Sciences Immunology Experience
Navitas Life Sciences' expert panel will utilize their insights, real-world learning, and best practices to enhance your immunology study experience.
The Centers for Disease Control and Prevention Flu Study
The Centers for Disease Control and Prevention(CDC) is the the United States’s national public health agency. The CDC Flu study is a 5-year initiative for the provision of pre- and post-immunization serum samples from eligible pediatric and adult participants vaccinated with the current seasonal influenza vaccine. Navitas Clinical Research (NCR, a part of Navitas Life Sciences) is actively involved in the design, maintenance, and implementation of the study. NCR is responsible for operational, regulatory, and data monitoring support of the sites. A large part of the effort is collection, tracking and shipping of large quantities of biological specimens to the CDC for immunological analysis. NCR maintains a database of all specimen aliquots and provides the International Air Transport Association (IATA) shipping manifest to sites, as well as reports on the specimens to the CDC.
Case Study: Adaptive design for a global Study for a First-in-Class Therapy for Critical Covid-19 Patient
Navitas Life Sciences provided end-to-end support to a US Based mid-size biotech company in the development of their first in class therapy for critically ill covid patients. The Phase I study had been conducted in the US, and the company needed a partner to conduct the Phase II study in multiple countries - USA, India and other potential countries.
Navitas Life Sciences’ experienced Medical writers, Medical Leads and Biostatistics teams collaborated to deliver a well designed innovative and adaptive, two stage study protocol within a short span.
Download this Case Study to Learn how we:
- Developed a robust study protocol
- Completed the study in a short span
- Received Appreciation from the USFDA
To learn more about our services and solutions, reach out to us at